| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 21 | KIT突变形式的抑制剂 | CN201110222445.0 | 2004-11-17 | CN102274230B | 2015-07-01 | E·布赫东格尔; D·法布罗 |
| 本发明涉及治疗特征为KIT的突变形式的依赖KIT的疾病，其中鉴定了突变KIT并施用了突变KIT的适当抑制剂，所述抑制剂选自米哚妥林、vatalanib和化合物A。 | ||||||
| 22 | 一种检测绿盲蝽抗药性的方法 | CN201310671058.4 | 2013-12-10 | CN103675253A | 2014-03-26 | 高希武; 刘晓岚; 谭瑶; 许新新; 冯晶晶; 甄从爱; 张帅 |
| 本发明提供了一种检测绿盲蝽抗药性的方法，在药剂的诊断剂量下制作诊断玻璃管，快速检测绿盲蝽田间种群对药剂的抗性水平，所述药剂为马拉硫磷、毒死蜱、灭多威、三氟氯氰菊酯、吡虫啉或硫丹；药剂的诊断剂量：马拉硫磷为67ng/cm2，毒死蜱为560ng/cm2，灭多威为620ng/cm2，三氟氯氰菊酯为3046ng/cm2，吡虫啉为886ng/cm2，硫丹为1092ng/cm2。本发明方法使用简便，结果直观明了，适用于田间快速检测绿盲蝽抗性水平，克服了传统生测方法用样本数量大、操作繁琐、费时等缺点，可用于快速检测绿盲蝽田间种群抗性水平。 | ||||||
| 23 | stathmin作为呋咱并苯并咪唑类药物应答的生物标记的用途 | CN201280005882.X | 2012-01-19 | CN103328978A | 2013-09-25 | H·A·雷恩; F·巴赫曼 |
| 本发明涉及stathmin作为生物标记用于预测针对化合物的应答，例如抗性，的用途，其中所述化合物是通式I的呋咱并苯并咪唑化合物。 | ||||||
| 24 | 用于肿瘤特征和标记物组鉴定,肿瘤分级的方法和用于癌的标记物组 | CN201080020971.2 | 2010-04-16 | CN102421920A | 2012-04-18 | E·王; 李杰; 邓迎海; A·EG·伦费林克; M·D·奥康纳-麦考特; E·普里西马 |
| 用于鉴定肿瘤特征的方法包括：获得各预测目标特征的3个不同标记物组，自肿瘤细胞获得样品基因表达信号，添加报告子以影响样品中的变化，用于允许评定肿瘤中的目标基因表达信号，将基因表达信号与报告子组合，将提取的基因表达信号与3个不同标记物组关联，根据以下顺序将指定分配给提取的基因表达信号：如果全部3个预测性基因表达信号组的关联预测其具有关注的特征，将其指定为恶性肿瘤；如果全部3个预测性基因表达信号组的关联预测其缺乏关注的特征，将其指定为良性肿瘤；及，如果全部3个预测性基因表达信号组的关联不提供相同的预测的临床结果，将所述肿瘤指定为“中等”；及，输出所述指定。 | ||||||
| 25 | KIT突变形式的抑制剂 | CN201110222445.0 | 2004-11-17 | CN102274230A | 2011-12-14 | E·布赫东格尔; D·法布罗 |
| 本发明涉及治疗特征为KIT的突变形式的依赖KIT的疾病，其中鉴定了突变KIT并施用了突变KIT的适当抑制剂，所述抑制剂选自米哚妥林、vatalanib和化合物A。 | ||||||
| 26 | 用于检测结核杆菌中的异烟肼敏感性的方法和试验片 | CN200980125894.4 | 2009-07-01 | CN102105596A | 2011-06-22 | 切替照雄; 安藤弘树; 末竹寿纪; 中村友彦 |
| 根据本发明，提供用于更准确地检测结核杆菌的异烟肼(INH)敏感性、即结核杆菌是否是INH耐性菌的新方法。本发明的检测结核杆菌中的异烟肼敏感性的方法包括以下步骤：获得检体中的结核杆菌的furA基因的步骤、以及对该获得的furA基因检测与异烟肼耐性有关的突变的步骤。根据需要，本发明的方法还可以包括检测结核杆菌的fabG1基因突变的步骤，优选可以与其他公知的异烟肼敏感性检测方法组合。 | ||||||
| 27 | 检测对大环内酯-林可酰胺-链阳性菌素b的可诱导抗性 | CN200880119411.5 | 2008-11-25 | CN101903533A | 2010-12-01 | C·余; C·M·高斯内尔; V·怀特利; D·J·图内尔 |
| 本发明的实施方案提供了一种测试板和方法，用于在自动化微生物鉴定(ID)和抗微生物易感性测定(AST)系统中检测微生物对大环内酯-林可酰胺-链阳性菌素b的可诱导抗性(iMLSb)。多孔测试板的孔含有大环内酯剂和林可酰胺剂以及大环内酯剂与林可酰胺剂二者的组合。测试板与液体培养基悬浮的微生物一起孵育，并置于自动化微生物鉴定(ID)和抗微生物易感性测定(AST)系统中。让测试板在系统内孵育，并监视孔内微生物的生长。 | ||||||
| 28 | 检测和调节肿瘤细胞对抗有丝分裂剂的敏感性的方法 | CN200880014915.0 | 2008-03-05 | CN101778637A | 2010-07-14 | 玛丽亚·卡瓦拉里斯; 颜佩佩 |
| 本发明涉及一种筛选肿瘤细胞对微管蛋白结合剂的抗性的方法，所述方法包括检测肿瘤细胞对II类、III类和IVb类β微管蛋白中的任何一种或多种的表达，其中II类、III类和IVb类β微管蛋白中的任何一种或多种的表达表明肿瘤细胞具有对微管蛋白结合剂的抗性或潜在抗性。 | ||||||
| 29 | 微生物检测方法和仪器 | CN200880019718.8 | 2008-04-18 | CN101680041A | 2010-03-24 | D·雷伊; C·巴特; L·M·特谢拉 |
| 本发明的实例涉及到选择性生物体检测，尤其是重组细菌噬菌体及使用其检测靶细菌以及检测此靶细菌中的特定核酸序列，从而可以检测此细菌表性的特性，如确定靶细菌对何种药物具有耐药性。此外，本发明还可涉及基于细菌噬菌体技术以用来检测和分析准备样品的样品准备装置。此装置成本低，易于使用并且不要求任何专业技术或附加的实验室设备。 | ||||||
| 30 | 用于脊髓损伤中抗Nogo－A抗体治疗的生物标记 | CN200680042608.4 | 2006-11-14 | CN101310183A | 2008-11-19 | A·金努宁; M·E·施瓦布; L·蒙塔尼; L·迪穆; A·K·米尔; L·施内尔 |
| 本公开的内容在基因表达水平证实受损脊髓和皮层运动区作为鞘内应用的抗Nogo－A抗体治疗的主要作用部位。该公开也提供用于通过评估选自如下至少一种基因的表达而监测受试者对包含抗Nogo－A抗体的药物应答的方法：钙黏着蛋白2、8、11或22；肝配蛋白A3或B2；Eph受体A3或A4；脑信号蛋白4A、4D、4F、6A或6B；丛蛋白B2；加帽蛋白(细肌丝，类凝溶胶蛋白)；酪蛋白激酶1δ；中心体肌动蛋白；凝溶胶蛋白；微管相关蛋白质τ；神经丝68；肌纤蛋白；嗅介蛋白1或3；γ干扰素；Rho－GDP解离抑制物1、二氢嘧啶酶相关蛋白(CRMP)1、2或5；突触核蛋白；淀粉状蛋白β(A4)PP结合性A1；淀粉状蛋白β(A4)前体样蛋白1或2；前列腺素E合酶；苯并二氮杂受体或双糖链蛋白聚糖。 | ||||||
| 31 | ＭＲＳＡ 검출 방법 및 이를 이용한 키트 | KR1020120126614 | 2012-11-09 | KR101289310B1 | 2013-07-24 | 김정욱 |
| PURPOSE: A method for detecting methicillin-resistant Staphylococcus aureus (MRSA) is provided to effectively detect MRSA through multiplex real-time PCR using a target gene-specific primer and a probe, and to easily distinguish MRSA from other strains. CONSTITUTION: A method for detection or quantitation of MRSA comprises the steps of: preparing a sample; amplifying a nucleotide sequence in the sample using SCCmec/orfX gene detection set, mecA gene detection set, and 16S rRNA gene detection set; and identifying an amplified result by fluorescence. MRSA exists in a sample when the difference (CtSCC) of Ct value between SCCmec/orfX and mecA is 4.7 or less or the difference (Ct16S) of Ct value between 16S rRNA and mecA is -1.72 or more. The SCCmec/orfX gene detection set contains: one or more forward primers selected from the group consisting of sequence numbers 1-6; one or more reverse primers selected from the group consisting of sequence numbers 7 and 8; and a probe of sequence number 9. The mecA gene detection set contains a primer pair of sequence numbers 10 and 11 and a probe of sequence number 12. The 16S rRNA gene detection set contains a primer pair of sequence numbers 13 and 14 and a probe of sequence number 15. | ||||||
| 32 | ＨＧＦ 유전자의 폴리 Ａ 반복수 변이 다형 검출용 프로브 및 그 용도 | KR1020120048994 | 2012-05-09 | KR1020120125969A | 2012-11-19 | 이구치아키; 히라이미츠하루 |
| PURPOSE: A probe for detecting HGF gene polymorphism is provided to detect polymorphism of poly A repeat number mutation. CONSTITUTION: A method for detecting polymorphism comprises: a step of contacting a probe for detecting polymorphism with a single-stranded nucleic acid in a sample to prepare a hybrid of a fluorescence-labeled oligonucleotide and single-stranded nucleic acid; a step of changing temperature of the sample containing hybrid and dissociate the hybrid; a step of measuring fluctuation of a fluorescence signal based on the dissociation of the hybrid; and a step of evaluating Tm value(dissociating temperature) of the hybrid based on the fluctuation of fluorescence signal. [Reference numerals] (AA,BB,CC) Temperature(°C) | ||||||
| 33 | 척수 손상에서의 항-ＮＯＧＯ-Ａ 항체 치료를 위한바이오마커 | KR1020087014422 | 2006-11-14 | KR1020080073748A | 2008-08-11 | 키누넨,아누; 슈바프,마르틴에.; 몬타니,라우라; 디모우,레다; 미르,아니스쿠스로; 슈넬,리사 |
| This disclosure of this invention confirms, at the level of gene expression, the injured spinal cord and motor cortex as the primary sites of action of the anti-Nogo-A antibody treatment applied intrathecally. The disclosure further provides methods for predicting the response of a subject to a medicament comprising an anti-Nogo-A antibody. | ||||||
| 34 | 아폽토시스-유도 사멸 수용체 작용제에 대한 내성을 감소시키는데 관련된 약제 및 방법 | KR1020077020026 | 2006-01-31 | KR1020070100415A | 2007-10-10 | 조우통; 킴벌리로버트피 |
| Provided herein is a method of reversing or preventing a target cell's resistance to a death receptor agonist. Also provided are methods of screening for biomarkers resistance of and monitoring resistance to death receptor agonists. Also provided are methods of selectively inducing apoptosis in a target cell, treating a subject with cancer, autoimmune or inflammatory diseases, comprising administering compositions provided herein. Further provided are compositions comprising agents that modulate CARD containing proteins. | ||||||
| 35 | 담도암 치료용 약물 감수성 예측용 조성물 | KR1020160120768 | 2016-09-21 | KR1020180032064A | 2018-03-29 | 송시영; 정다운; 박수빈; 김선아 |
| 본발명은담도암치료용약물에대하여감수성을예측할수 있는유전자, 단백질및/또는마이크로 RNA의발현수준을측정하는제제를포함하는조성물, 상기조성물을포함하는키트를제공한다. 또한, 상기담도암치료용약물에대하여유전자, 단백질및/또는마이크로 RNA의발현수준을측정을통한감수성을예측할수 있는방법을제공한다. | ||||||
| 36 | 아폽토시스-유도 사멸 수용체 작용제에 대한 내성을 감소시키는데 관련된 약제 및 방법 | KR1020077020026 | 2006-01-31 | KR101292961B1 | 2013-08-02 | 조우통; 킴벌리로버트피 |
| 본 발명은 사멸 수용체 작용제에 대한 표적 세포의 내성을 제거하거나 방지하는 방법에 관한 것이다. 또한, 본 발명은 사멸 수용체 작용제에 대한 내성의 생물표지를 선별하는 방법 및 상기 내성을 모니터링하는 방법에 관한 것이다. 뿐만 아니라, 본 발명은 표적 세포에서 아폽토시스를 선택적으로 유도하는 방법, 및 본원에 제공되는 조성물을 투여함을 포함하는, 암, 자가 면역 질환 또는 염증 질환에 걸린 개체를 치료하는 방법에 관한 것이다. 본 발명은 또한 CARD 함유 단백질을 조절하는 약제를 포함하는 조성물에 관한 것이다. 사멸 수용체 작용제, 아폽토시스 유도, CARD 함유 단백질. | ||||||
| 37 | 다제 내성 포도상구균의 이뮤노크로마토그래피 검출법 및 진단 키트 | KR1020087016976 | 2006-12-14 | KR1020080080364A | 2008-09-03 | 이또,히로미 |
| It is intended to provide an immunochromatographic detection device which detects PBP2' specifically produced by a multidrug-resistant Staphylococcus bacterium by an immunochromatographic detection method sensitively, simply and rapidly and is capable of determining infection with a multidrug-resistant Staphylococcus, a diagnostic method using the detection device, and a diagnostic kit including the detection device. The invention is directed to the immunochromatographic detection device for detecting a multidrug-resistant Staphylococcus which includes a sample supply unit which supplies a sample solution which is assumed to contain a multidrug-resistant Staphylococcus or a solution which is assumed to contain PBP2' released from a cell wall by a pretreatment of a sample onto a sheet-shaped solid-phase support, a labeling reagent unit which retains a labeling reagent in which an antibody specifically binding to PBP2' is labeled spreadable on the solid-phase support, and a trapping reagent unit in which a trapping reagent capable of trapping a complex of PBP2' and the labeling reagent by specifically binding to the complex is immobilized, and in which an amphoteric surfactant, an anionic surfactant and/or a nonionic surfactant is contained in the trapping reagent unit or in the solid-phase support upstream of the trapping reagent unit. | ||||||
| 38 | 黄色ブドウ球菌(Staphylococcus aureus)α毒素に特異的に結合する抗体及び使用方法 | JP2017023905 | 2017-02-13 | JP6367393B2 | 2018-08-01 | セルマン,ブレット; トカツィク,クリスティーン; フア,レイ; チャウダリー,パーサ; ヴァーキー,リーナ; ダムシュローダー,メリッサ; ペン,リー; オガネスヤン,ヴァエ; ヒリアード,ジェームズ,ジョンソン |
| 39 | β−ラクタマーゼ耐性の質量分析測定 | JP2015202925 | 2015-10-14 | JP6286406B2 | 2018-02-28 | マルクス コストシェヴァ; カーステン ミッチェルマン; カトリン スパービーア |
| 40 | 生理活性脂質の使用 | JP2017530706 | 2015-12-01 | JP2017538704A | 2017-12-28 | モジュガン マソーディ，; エル ハディ ママドゥー ディオウム， |
| 本発明は、対象における炎症性疾患の治療及び/又は予防に使用するための酸素化脂肪酸アシルグリセロールを提供する。【選択図】なし | ||||||
QQ群二维码
意见反馈
意见反馈